Everand Logo

Welcome to Everand!

  • STAT

    Legendary biotech financier Sam Isaly steps down following sexual harassment allegations

    Biotech financier Sam Isaly is stepping down from OrbiMed Advisors following a barrage of sexual harassment allegations published by STAT.
    by Damian Garde Dec 08, 2017 3 minutes

    Sam Isaly, founder of biotech’s largest and most powerful biotech hedge fund, is stepping down from his leadership role at OrbiMed Advisors following a barrage of sexual harassment allegations published by STAT.

    OrbiMed put out a statement on Thursday night asserting that Isaly is retiring “pursuant to years-long succession planning discussions.” However as recently as Monday, when STAT interviewed Isaly about the allegations against him, he said there was “no planned date” for his retirement.

    Isaly’s abrupt departure comes hours after STAT sought comments from the firm about still more allegations of misconduct from

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related Books & Audiobooks